SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Dallas’ own Match Group announced a public health partnership with the Biden White House to help promote Covid-19 vaccination across its portfolio of dating apps

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.